A Phase 4 interventional study of Bedaquiline and Levofloxacin in Tuberculosis, Multidrug-Resistant, sponsored by Beijing Chest Hospital. Recruiting at 17 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-01-18.
Sponsored by Beijing Chest Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing bedaquiline in Tuberculosis, Multidrug-Resistant — 3 open to participants now, 5 under way, 3 of them phase 3. bedaquiline · Tuberculosis, Multidrug-Resistant.
Among the 20 studies testing bedaquiline in Tuberculosis, Multidrug-Resistant, this one is the 9th largest by planned enrollment, is one of 2 that started in 2022, is the only one in phase 4, and was the 17th registered.
132 studies on the registry are indexed under Tuberculosis, Multidrug-Resistant; 25 are open to participants now.
Browse Tuberculosis, Multidrug-Resistant studies →3 of the 20 studies testing bedaquiline in Tuberculosis, Multidrug-Resistant are open now, in 7 countries. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University of California, San Francisco · Sites in Mongolia, Pakistan, Peru and 2 more countries
Ages 14+
By country, each count listing its studies:
bedaquiline: first FDA approval 2012 (SIRTURO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 20 Tuberculosis, Multidrug-Resistant studies recruiting now, 12 (60%) set no upper age limit and 7 (35%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 11 · Phase 3 12 · Phase 4 1
First in 2007; this study’s year is marked. 2 started in 2022.
This study's planned enrollment of 212 is close to the median of 194 across 88 interventional studies indexed under Tuberculosis, Multidrug-Resistant.
Median enrollment 195 across the 20 interventional studies. Of the 13 that completed or were terminated, 6 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 20 have an industry lead sponsor. The 10 most frequent:
Beijing Chest Hospital is the lead sponsor of 31 studies on the registry; 13 are open to participants now.
Beijing Chest Hospital has 5 studies filed under Tuberculosis, Multidrug-Resistant — fewer than ten, so there is no comparison to draw.
2 of the studies testing bedaquiline in Tuberculosis, Multidrug-Resistant that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06649721Phase 3Huashan HospitalInnovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis:BDLL Chinese Cohort | 2027-02-28 |
| NCT03828201Boston UniversityEfficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies testing bedaquiline in Tuberculosis, Multidrug-Resistant, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate efficacy and safety of an oral bedaquiline-containing multidrug-resistant tuberculosis (MDR-TB) short-course regimen (SCR) compared to an oral SCR not including bedaquiline at the end of treatment in participants with pulmonary MDR-TB in China.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive an oral dose of bedaquiline 400 milligrams (mg) once daily for first 2 weeks followed by bedaquiline 200 mg thrice a week for 22 weeks (with at least 48 hours between doses) in combination with oral doses of levofloxacin (LFX) up to 1000 mg (weight-based), cycloserine (CS) up to 750 mg (weight-based), clofazimine (CFZ) 100 mg daily for 40 weeks and linezolid \[LZD\] 600 mg daily for at least 24 weeks . If a participant is still sputum culture-positive for Mycobacterium tuberculosis by Week 16, bedaquiline treatment will be extended from Week 24 to Week 40.
Drug: Bedaquiline · Drug: Levofloxacin · Drug: Linezolid · Drug: Cycloserine · Drug: Clofazimine
Participants will receive oral doses of LFX up to 1000 mg (weight-based), CS up to 750 mg (weight-based), CFZ 100 mg, Pyrazinamide (PZA) up to 2000 mg (weight-based), Protionamide (PTO) up to 800 mg (weight-based) daily for first 16 weeks and LZD 600 mg daily for at least 24 weeks.
Drug: Levofloxacin · Drug: Linezolid · Drug: Cycloserine · Drug: Clofazimine · Drug: Pyrazinamide · Drug: Protionamide
Bedaquiline uncoated tablets will be administered orally.
Also known as: SIRTURO
Levofloxacin filmcoated will be administered orally
Linezolid tablets will be administered orally
Cycloserine capsules will be administered orally.
Clofazimine capsules will be administered orally.
Pyrazinamide tablets will be administered orally.
Protionamide enteric-coated tablets will be administered orally.
Percentage of Participants with a Favorable Treatment Outcome at the End of Treatment
Percentage of participants with a favorable treatment outcome at the end of treatment will be reported. A participant's outcome will be classified as favorable if their last 3 culture results by the end of treatment are negative unless they have previously been classified as unfavorable. These 3 cultures must be taken on separate visits; the latest of which being no more than 8 weeks prior to the end of treatment.
Time frame: At the end of treatment (Week 40)
Percentage of Participants with a Favorable Treatment Outcome at 48 Weeks Post the End of Treatment
Percentage of participants with a favorable treatment outcome at 48 weeks post the end of treatment will be reported. A participant's outcome will be classified as favorable if their last 3 culture results by the end of treatment are negative unless they have previously been classified as unfavorable. These 3 cultures must be taken on separate visits; the latest of which being no more than 8 weeks prior to the end of treatment.
Time frame: At 48 weeks post the end of treatment (Week 88)
Percentage of Participants Achieving Treatment Success at the end of Treatment
Percentage of participants achieving treatment success at the end of treatment will be reported. Treatment success is achieved if participants completed their prescribed tuberculosis (TB) treatment; or if their last 3 culture results are negative by the end of treatment, these 3 cultures must be taken on separate visits and should be after the initial 6-month treatment period.
Time frame: At the end of treatment (Week 40)
Percentage of Participants with a Modified Favorable Treatment Outcome at the end of Treatment and at 48 Weeks Post end of Treatment
Percentage of participants with a modified favorable treatment outcome at the end of treatment and at 48 weeks post end of treatment will be reported. A participant's treatment outcome will be classified as modified favorable if their last 2 culture results by the end of treatment are negative unless they have previously been classified as unfavorable. These 2 cultures must be taken on separate visits; the latest of which being no more than 8 weeks prior to the end of treatment.
Time frame: At the end of treatment (Week 40) and at 48 weeks post end of treatment (Week 88)
Percentage of Participants Experiencing All-cause Mortality
Percentage of participants experiencing all-cause mortality will be reported.
Time frame: Up to Week 88
Percentage of Participants Experiencing Grade 3 or Greater Treatment-emergent Adverse Events (TEAEs) During Study Treatment and Follow-up
Percentage of participants experiencing grade 3 or greater TEAEs during study treatment and follow-up will be reported. An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are defined as any event that begins or worsens in severity after initiation of study drug through to the end of study. An assessment of severity grade will be made using the following 5 general categorical descriptors based on division of acquired immunodeficiency syndrome (AIDS) grading for AE severity assessment. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening, and Grade 5= Death.
Time frame: During study treatment and follow-up (From Week 1 up to Week 88)
Percentage of Participants Experiencing TEAEs
Percentage of participants experiencing TEAEs will be reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are defined as any event that begins or worsens in severity after initiation of study drug through to the end of study.
Time frame: From Week 1 up to Week 88
Percentage of Participants with TB Relapses and Re-infections During the Treatment-free Follow-up Phase
Percentage of participants with TB relapses and re-infections during the treatment-free follow-up phase will be reported.
Time frame: During the treatment-free follow-up phase (Up to 48 weeks)
Percentage of Participants Whose Isolates Develop Resistance to Bedaquiline and Other Drugs Used in the Regimen
Percentage of participants whose isolates develop resistance to bedaquiline and other drugs used in the regimen will be reported.
Time frame: Up to Week 88
Started May 2022 (actual). Primary completion is estimated for Aug 2025, 38 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bedaquiline · Pyrazinamide
Tuberculosis, Multidrug-Resistant →
Beijing Chest Hospital